Harvard University still holds a patent for any animal genetically engineered to develop cancer after an appeal against its patent broke up without conclusion last week. Some anti-patent campaigners now predict that Harvard will emerge from the appeal with a restricted patent, for an "onco-rodent".
The appeal was held by the European patent office after objections to Harvard's patent from campaigners across Europe. The appeal will continue in writing.
Register to continue
Why register?
- Registration is free and only takes a moment
- Once registered, you can read 3 articles a month
- Sign up for our newsletter
Subscribe
Or subscribe for unlimited access to:
- Unlimited access to news, views, insights & reviews
- Digital editions
- Digital access to 罢贬贰’蝉 university and college rankings analysis
Already registered or a current subscriber?
Please or to read this article.